Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M C Y de Wit

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Intellectual Disability Research : JIDR|November 27, 2023
Child characteristics associated with child quality of life and parenting stress in Angelman syndromeD A Hagenaar, K G C B Bindels-de Heus, K Lubbers, et al.
Molecular Syndromology|October 30, 2010
Distinctive Phenotypic Abnormalities Associated with Submicroscopic 21q22 Deletion Including DYRK1AR Oegema, A de Klein, A J Verkerk, et al.
BMC Psychiatry|January 4, 2024
Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trialsA R Müller, B den Hollander, P M van de Ven, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Intellectual Disability Research : JIDR|November 27, 2023
Child characteristics associated with child quality of life and parenting stress in Angelman syndromeD A Hagenaar, K G C B Bindels-de Heus, K Lubbers, et al.
Molecular Syndromology|October 30, 2010
Distinctive Phenotypic Abnormalities Associated with Submicroscopic 21q22 Deletion Including DYRK1AR Oegema, A de Klein, A J Verkerk, et al.
BMC Psychiatry|January 4, 2024
Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trialsA R Müller, B den Hollander, P M van de Ven, et al.
Pageof 2